[go: up one dir, main page]

NO20054136L - Imidazol-4-yl-etynyl-pyridin-derivater - Google Patents

Imidazol-4-yl-etynyl-pyridin-derivater

Info

Publication number
NO20054136L
NO20054136L NO20054136A NO20054136A NO20054136L NO 20054136 L NO20054136 L NO 20054136L NO 20054136 A NO20054136 A NO 20054136A NO 20054136 A NO20054136 A NO 20054136A NO 20054136 L NO20054136 L NO 20054136L
Authority
NO
Norway
Prior art keywords
imidazol
pyridine derivatives
ylethynyl
disease
alkyl
Prior art date
Application number
NO20054136A
Other languages
English (en)
Other versions
NO20054136D0 (no
Inventor
Sabine Kolczewski
Bernd Buettelmann
Georg Jaeschke
Eric Vieira
Simona Maria Ceccarelli
Richard Hugh Phillip Porter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20054136D0 publication Critical patent/NO20054136D0/no
Publication of NO20054136L publication Critical patent/NO20054136L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

4-[1-aryl-imidazo1-4-yletynyl]-2-alkyl-pyridin- og 1-heteroaryl-imidazol-4-yletynyl]-2- alkyl-pyridin-derivater og farmasøytisk akseptable salter derav, for behandling eller forebygging av lidelser som er fullstendig eller delvis mediert av metabotrop glutamatreseptor 5, f.eks. akutte, traumatiske og kroniske, degenerative prosesser i nervesystemet, så som Alzheimers sykdom, senil demens, Parkinsons sykdom, Huntingtons chorea, amyotrofisk lateralsklerose og multippel sklerose, psykiske sykdommer så som schizofreni og angst, depresjon, smerte og medikamentavhengighet.
NO20054136A 2003-03-10 2005-09-06 Imidazol-4-yl-etynyl-pyridin-derivater NO20054136L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03004952 2003-03-10
PCT/EP2004/002276 WO2004080998A1 (en) 2003-03-10 2004-03-05 Imidazol-4-yl-ethynyl-pyridine derivatives

Publications (2)

Publication Number Publication Date
NO20054136D0 NO20054136D0 (no) 2005-09-06
NO20054136L true NO20054136L (no) 2005-09-26

Family

ID=32981724

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054136A NO20054136L (no) 2003-03-10 2005-09-06 Imidazol-4-yl-etynyl-pyridin-derivater

Country Status (30)

Country Link
US (1) US7153874B2 (no)
EP (1) EP1606277B8 (no)
JP (1) JP4404896B2 (no)
KR (1) KR100742019B1 (no)
CN (1) CN100358889C (no)
AR (1) AR043501A1 (no)
AT (1) ATE395345T1 (no)
AU (1) AU2004220382B2 (no)
BR (1) BRPI0408093A (no)
CA (1) CA2516682C (no)
CL (1) CL2004000449A1 (no)
CO (1) CO5601027A2 (no)
DE (1) DE602004013746D1 (no)
DK (1) DK1606277T3 (no)
ES (1) ES2305739T3 (no)
HR (1) HRP20050774A2 (no)
IL (1) IL170129A (no)
MX (1) MXPA05009524A (no)
MY (1) MY135491A (no)
NO (1) NO20054136L (no)
NZ (1) NZ541643A (no)
PA (1) PA8597301A1 (no)
PE (1) PE20041061A1 (no)
PL (1) PL1606277T3 (no)
PT (1) PT1606277E (no)
RU (1) RU2342383C2 (no)
SI (1) SI1606277T1 (no)
TW (1) TWI292318B (no)
WO (1) WO2004080998A1 (no)
ZA (1) ZA200506834B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7452909B2 (en) * 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
DE602005007350D1 (de) * 2004-06-01 2008-07-17 Hoffmann La Roche Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors
HRP20080363T3 (hr) * 2004-06-01 2008-09-30 F. Hoffmann - La Roche Ag Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
DE102006011574A1 (de) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
MX2009002496A (es) * 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN101568531B (zh) 2006-12-21 2013-11-13 弗·哈夫曼-拉罗切有限公司 Mglur5受体拮抗剂的多晶型物
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8334287B2 (en) * 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
HUE025031T2 (en) 2011-04-26 2016-02-29 Hoffmann La Roche Ethinyl derivatives as positive allosteric modulators of MGLUR5
UA116023C2 (uk) 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
EP3400220B1 (en) * 2016-01-05 2021-03-24 Hua Medicine (Shanghai) Ltd. Pyrazole derivatives
CN110312718B (zh) 2017-01-10 2023-02-28 拜耳公司 作为害虫防治剂的杂环烯衍生物
UY37556A (es) 2017-01-10 2018-07-31 Bayer Ag Derivados heterocíclicos como pesticidas
JP2023504177A (ja) * 2019-12-02 2023-02-01 エフ．ホフマン－ラ ロシュ アーゲー アルキニル－（ヘテロアリール）－カルボキサミドｈｃｎ１阻害剤
CN111416154B (zh) * 2020-05-22 2021-08-06 松山湖材料实验室 高电压锂离子电池电解液硅基吡啶添加剂、电解液及其电池
JP2024511476A (ja) 2021-03-27 2024-03-13 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺微生物イソニコチンアミド誘導体
EP4433460A2 (en) 2021-11-19 2024-09-25 Syngenta Crop Protection AG Microbiocidal isonicotinic amide derivatives
WO2024132901A1 (en) 2022-12-19 2024-06-27 Syngenta Crop Protection Ag Microbiocidal pyridazine dihydrooxadiazine derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3303199A (en) * 1963-07-15 1967-02-07 Geigy Chem Corp Certain imidazolone derivatives and process for making same
US3341548A (en) * 1964-04-29 1967-09-12 Hoffmann La Roche Nitroimidazoles and their preparation
DE2035905A1 (de) 1970-07-20 1972-02-03 Chemische Fabrik Stockhausen & Cie.,4150Krefeld Imidazolverbindungen und deren Herstellungsverfahren
CA1174673A (en) * 1981-02-27 1984-09-18 Walter Hunkeler Imidazodiazepines
US4711962A (en) * 1984-10-18 1987-12-08 Stauffer Chemical Company Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles
US4868181A (en) * 1986-08-04 1989-09-19 E. I. Du Pont De Nemours And Company 1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
US4882343A (en) * 1987-08-28 1989-11-21 G. D. Searle & Co. Biarylalkylimidazole derivatives as anti-depressants
WO1991000277A1 (en) 1989-06-30 1991-01-10 E.I. Du Pont De Nemours And Company Substituted imidazoles
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
IL134168A0 (en) 1997-08-14 2001-04-30 Hoffmann La Roche Heterocyclic vinylethers against neurological disorders
AU780009B2 (en) 1999-08-31 2005-02-24 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof
HUP0400570A3 (en) 2000-12-04 2004-09-28 Hoffmann La Roche Phenylethenyl or phenylethinyl heteroaril derivatives as glutamate receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them
AU2002360621B2 (en) * 2001-12-19 2007-01-25 Merck & Co., Inc. heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5

Also Published As

Publication number Publication date
ZA200506834B (en) 2006-05-31
CN1759111A (zh) 2006-04-12
ES2305739T3 (es) 2008-11-01
CL2004000449A1 (es) 2005-01-07
PT1606277E (pt) 2008-07-08
NZ541643A (en) 2008-03-28
TWI292318B (en) 2008-01-11
DK1606277T3 (da) 2008-08-18
EP1606277B1 (en) 2008-05-14
CN100358889C (zh) 2008-01-02
MY135491A (en) 2008-04-30
PL1606277T3 (pl) 2008-10-31
EP1606277A1 (en) 2005-12-21
WO2004080998A1 (en) 2004-09-23
BRPI0408093A (pt) 2006-02-14
CA2516682C (en) 2010-02-02
NO20054136D0 (no) 2005-09-06
JP4404896B2 (ja) 2010-01-27
MXPA05009524A (es) 2005-10-18
RU2342383C2 (ru) 2008-12-27
AU2004220382A1 (en) 2004-09-23
AU2004220382B2 (en) 2007-08-02
EP1606277B8 (en) 2008-10-15
KR20050109074A (ko) 2005-11-17
PA8597301A1 (es) 2004-09-16
PE20041061A1 (es) 2005-01-22
HK1089443A1 (zh) 2006-12-01
ATE395345T1 (de) 2008-05-15
IL170129A (en) 2013-02-28
JP2006519802A (ja) 2006-08-31
HRP20050774A2 (en) 2006-09-30
KR100742019B1 (ko) 2007-07-23
TW200423935A (en) 2004-11-16
AR043501A1 (es) 2005-08-03
US20040229917A1 (en) 2004-11-18
CA2516682A1 (en) 2004-09-23
SI1606277T1 (sl) 2008-08-31
RU2005131165A (ru) 2007-04-20
DE602004013746D1 (de) 2008-06-26
US7153874B2 (en) 2006-12-26
CO5601027A2 (es) 2006-01-31

Similar Documents

Publication Publication Date Title
NO20054136L (no) Imidazol-4-yl-etynyl-pyridin-derivater
MA27134A1 (fr) Derives diarylcycloalkyle, leur procede de preparation et leur utilisation en tant qu'activateurs des ppar
NO20082768L (no) Levodopa prodroge mesylat, sammensetninger og anvendelser derav
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
NO20056130L (no) Nye substituerte 3-svovelindoler
CY1111206T1 (el) Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων
WO2004071442A3 (en) Novel bicyclic compounds and compositions
EA200500250A1 (ru) Аналоги тиомолибдата и их применение
NO20083197L (no) Substituert cinnolin-derivater som GABAA-reseptor modulatorer og metode for deres syntese
WO2005123703A8 (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
BRPI0417203A (pt) uso em doenças degenerativas do cérebro
PL1706113T3 (pl) Sposób wytwarzania chlorowodorku 4-(2-dipropyloaminoetylo)-1,3-dihydro-2H-indol-2-onu
ATE402176T1 (de) Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
NO20053972L (no) Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav.
EP2982668A3 (en) 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders
WO2008020306A3 (en) Isoindole derivatives
DK1272208T3 (da) Anvendelse af VEGF 165 og homologer til at behandle neuron-sygdomme
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
WO2007127393A3 (en) Treatment and screening methods for promoting neurogenesis
WO2008142896A1 (ja) パップ剤及びパップ剤の製造方法
WO2022204362A3 (en) Compositions and methods for treating a neurodegenerative or developmental disorder
NO20090812L (no) Fenyl-prenyl-eter derivater for behandling av kognitive, neurodegenerative eller neurone sykdommer eller lidelser
WO2007021575A3 (en) Acetylenic piperazines as metabotropic glutamate receptor antagonists
DOP2004000843A (es) Derivados de imidazol-4-il-etinil-piridina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application